Cargando…
Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study
BACKGROUND: Drug-induced interstitial lung disease (ILD) is one of the most serious adverse reactions associated with the molecularly targeted drugs. Panitumumab has been approved for advanced or recurrent colorectal cancer. Although there were no adverse reaction reports of ILD in panitumumab monot...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Japan
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666285/ https://www.ncbi.nlm.nih.gov/pubmed/25967287 http://dx.doi.org/10.1007/s10147-015-0834-3 |